Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RBX2660 (Rebyota) for recurrent C. difficile infection
NCT02299570Phase 2Completed
- Sponsor
- Rebiotix Inc.
- Start
- Dec 2014
- Primary completion
- Jan 2016
- Modality
- Live Biotherapeutic Products
- Countries
- 2
01
Overview
A Phase 2 trial of RBX2660 in recurrent Clostridioides difficile infection (rCDI), sponsored by Rebiotix Inc.. Started Dec 2014; status: completed.
02
Drugs
RBX2660
03
Conditions
recurrent Clostridioides difficile infection (rCDI)
Beyond the preview
Go deeper on NCT02299570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02299570.